Stock of The Day: What’s Propelling Abeona Therapeutics Inc to Increase So Much?

Stock of The Day: What's Propelling Abeona Therapeutics Inc to Increase So Much?

The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) is a huge mover today! About 820,375 shares traded hands or 127.78% up from the average. Abeona Therapeutics Inc (NASDAQ:ABEO) has risen 139.44% since March 15, 2016 and is uptrending. It has outperformed by 133.95% the S&P500.
The move comes after 5 months positive chart setup for the $257.56 million company. It was reported on Oct, 18 by Barchart.com. We have $10.58 PT which if reached, will make NASDAQ:ABEO worth $100.45 million more.

Analysts await Abeona Therapeutics Inc (NASDAQ:ABEO) to report earnings on November, 15. They expect $-0.13 EPS, up 31.58% or $0.06 from last year’s $-0.19 per share. After $-0.20 actual EPS reported by Abeona Therapeutics Inc for the previous quarter, Wall Street now forecasts -35.00% EPS growth.

Abeona Therapeutics Inc (NASDAQ:ABEO) Ratings Coverage

Out of 3 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Abeona Therapeutics has been the topic of 4 analyst reports since December 16, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Cantor Fitzgerald on Thursday, September 8. On Wednesday, December 16 the stock rating was initiated by Maxim Group with “Buy”. As per Thursday, September 29, the company rating was maintained by Maxim Group. Rodman & Renshaw reinitiated the shares of ABEO in a report on Wednesday, April 20 with “Buy” rating.

More recent Abeona Therapeutics Inc (NASDAQ:ABEO) news were published by: Streetinsider.com which released: “Abeona Therapeutics (ABEO) Announces EU Orphan Drug Designation for ABO-102 …” on October 18, 2016. Also Seekingalpha.com published the news titled: “Abeona Therapeutics: A Promising Gene Therapy Story” on October 10, 2016. Benzinga.com‘s news article titled: “263% Upside Seen In Abeona Therapeutics” with publication date: September 21, 2016 was also an interesting one.

Abeona Therapeutics, Inc. , formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma products for rare diseases. The company has a market cap of $257.56 million. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV) gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. It currently has negative earnings. The Firm is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing approach to gene therapy program for rare blood diseases.

ABEO Company Profile

Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., incorporated on June 22, 1989, is focused on developing and delivering gene therapy and plasma products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV) gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Firm is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease (COPD) using its salt diafiltration (SDF) ethanol-free process. The Company’s product pipeline also consists of MuGard and ProdiGard.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment